These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33844174)

  • 1. Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study.
    Codjia T; Rebibo L; François A; Lagnel C; Huet E; Bekri S; Pattou F; Régimbeau JM; Schwarz L
    Obes Surg; 2021 Aug; 31(8):3548-3556. PubMed ID: 33844174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.
    Lassailly G; Caiazzo R; Hollebecque A; Buob D; Leteurtre E; Arnalsteen L; Louvet A; Pigeyre M; Raverdy V; Verkindt H; Six MF; Eberle C; Patrice A; Dharancy S; Romon M; Pattou F; Mathurin P
    Eur J Gastroenterol Hepatol; 2011 Jun; 23(6):499-506. PubMed ID: 21499110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.
    Poynard T; Lassailly G; Diaz E; Clement K; Caïazzo R; Tordjman J; Munteanu M; Perazzo H; Demol B; Callafe R; Pattou F; Charlotte F; Bedossa P; Mathurin P; Ratziu V;
    PLoS One; 2012; 7(3):e30325. PubMed ID: 22431959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compare the Combined Diagnostic Accuracy of Transient Elastography and Visual Liver Score in Assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and Compare it with Liver Biopsy in Morbidly Obese Patients Undergoing Bariatric Surgery: An Observational Study.
    Sharma D; Anand G; Meena S; Bhardwaj V
    Obes Surg; 2024 Apr; 34(4):1247-1256. PubMed ID: 38411879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability of Non-invasive Liver Fibrosis Assessment Tools Versus Biopsy in Pre- and Post-bariatric Surgery Patients with Non-alcoholic Fatty Liver Disease.
    Schwenger KJP; Alali M; Ghorbani Y; Fischer SE; Jackson TD; Okrainec A; Allard JP
    Obes Surg; 2023 Jan; 33(1):247-255. PubMed ID: 36464738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bariatric Surgery in Nonalcoholic Fatty Liver Disease (NAFLD): Impact Assessment Using Paired Liver Biopsy and Fibroscan.
    Agarwal L; Aggarwal S; Shalimar ; Yadav R; Dattagupta S; Garg H; Agarwal S
    Obes Surg; 2021 Feb; 31(2):617-626. PubMed ID: 33052552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibromax and inflamatory markers cannot replace liver biopsy in the evaluation of non-alcoholic fatty liver disease.
    Lardi LL; Lul RM; Port GZ; Coral GP; Peres A; Dornelles GP; Branco F; Fernandes S; Leães CG; Mattos AA; Buss C; Tovo CV
    Minerva Gastroenterol (Torino); 2022 Mar; 68(1):85-90. PubMed ID: 32700499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis.
    Lassailly G; Caiazzo R; Ntandja-Wandji LC; Gnemmi V; Baud G; Verkindt H; Ningarhari M; Louvet A; Leteurtre E; Raverdy V; Dharancy S; Pattou F; Mathurin P
    Gastroenterology; 2020 Oct; 159(4):1290-1301.e5. PubMed ID: 32553765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight Loss After Bariatric Surgery Predicts an Improvement in the Non-alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score.
    Yeo SC; Ong WM; Cheng KSA; Tan CH
    Obes Surg; 2019 Apr; 29(4):1295-1300. PubMed ID: 30635812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
    Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
    Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit-risk of intraoperative liver biopsy during bariatric surgery: review and perspectives.
    Barbois S; Arvieux C; Leroy V; Reche F; Stürm N; Borel AL
    Surg Obes Relat Dis; 2017 Oct; 13(10):1780-1786. PubMed ID: 28935200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
    Bril F; McPhaul MJ; Caulfield MP; Castille JM; Poynard T; Soldevila-Pico C; Clark VC; Firpi-Morell RJ; Lai J; Cusi K
    J Investig Med; 2019 Feb; 67(2):303-311. PubMed ID: 30309884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictive role of parathyroid hormone for non-alcoholic fatty liver disease based on invasive and non-invasive findings in candidates of bariatric surgery.
    Jamialahmadi T; Nematy M; Jangjoo A; Goshayeshi L; Abdalla MA; Akhlaghi S; Sathyapalan T; Sahebkar A
    Eat Weight Disord; 2022 Mar; 27(2):693-700. PubMed ID: 33999371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stage of fibrosis is not a predictive determinant of weight loss in patients undergoing bariatric surgery.
    Brol MJ; Drebber U; Yu X; Schierwagen R; Gu W; Plamper A; Klein S; Odenthal M; Uschner FE; Praktiknjo M; Trebicka J; Rheinwalt KP
    Surg Obes Relat Dis; 2024 Aug; 20(8):759-766. PubMed ID: 38522962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS.
    Smiderle CA; Coral GP; DE Carli LA; Mattos AA; Mattos AZ; Tovo CV
    Arq Gastroenterol; 2021; 58(2):139-144. PubMed ID: 34231659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
    Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
    World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.
    Lassailly G; Caiazzo R; Buob D; Pigeyre M; Verkindt H; Labreuche J; Raverdy V; Leteurtre E; Dharancy S; Louvet A; Romon M; Duhamel A; Pattou F; Mathurin P
    Gastroenterology; 2015 Aug; 149(2):379-88; quiz e15-6. PubMed ID: 25917783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
    Lemoine M; Assoumou L; De Wit S; Girard PM; Valantin MA; Katlama C; Necsoi C; Campa P; Huefner AD; Schulze Zur Wiesch J; Rougier H; Bastard JP; Stocker H; Mauss S; Serfaty L; Ratziu V; Menu Y; Schlue J; Behrens G; Bedossa P; Capeau J; Ingiliz P; Costagliola D;
    J Acquir Immune Defic Syndr; 2019 Apr; 80(4):e86-e94. PubMed ID: 30570529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.
    Weiner RA
    Dig Dis; 2010; 28(1):274-9. PubMed ID: 20460923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.